Abstract | PURPOSE: METHODS: We report a case of a patient with a biopsy proven prostate cancer showing clinical and pathologic evidence of regression following administration of GCP. The patient was enrolled in an Institutional Review Board (IRB)-approved protocol and received GCP for 6 weeks prior to radical prostatectomy. RESULTS: The patient's prostate-specific antigen (PSA) decreased from an initial value of 19.7 to 4.2 ng/mL after 44 days of low-dose GCP. No cancer was identified in the radical prostatectomy specimen and no side effects were observed in this patient. CONCLUSION: This case suggests that GCP, which has shown potent inhibitory effects against prostate cancer in vitro, may have some potential activity in the treatment and prevention of prostate cancer.
|
Authors | Mohamed A Ghafar, Erica Golliday, Jonathan Bingham, Mahesh M Mansukhani, Aristotelis Georgios Anastasiadis, Aaron E Katz |
Journal | Journal of alternative and complementary medicine (New York, N.Y.)
(J Altern Complement Med)
Vol. 8
Issue 4
Pg. 493-7
(Aug 2002)
ISSN: 1075-5535 [Print] United States |
PMID | 12230910
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Biomarkers, Tumor
- Polysaccharides
- Genistein
- Prostate-Specific Antigen
|
Topics |
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Basidiomycota
- Biomarkers, Tumor
(blood)
- Dose-Response Relationship, Drug
- Genistein
(pharmacology, therapeutic use)
- Humans
- Lentinula
- Male
- Middle Aged
- Mycelium
- Polysaccharides
(therapeutic use)
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(drug therapy, immunology, pathology)
- Reishi
- Remission Induction
- Treatment Outcome
|